WHO European Region · country profile

HIV, PrEP and sexual health access in Uzbekistan

Name: HIV medicine, PrEP and sexual health access in Uzbekistan
Creator: SHAPE

Uzbekistan: 19% of verified HIV medicine records are reimbursed; PrEP is available and reimbursed; sexuality education is classified as highly restricted. Compare medicines, prevention, reproductive rights and migrant healthcare access, with sources and the date each record was last checked.

Last checked 14/09/2026 · Sources cited on every record

Colour shows the share of verified HIV medicines that are reimbursed.

HIV medicines19% reimbursed5 of 26 verified records PrEPReimbursed883 PrEP recipients (2024; UNAIDS GAM)DoxyPEPNot available / no guidelinesNational access and guidance Sexuality educationHighly restrictedPolicy framework Family planning & abortionRestrictedAbortion law and contraception Migrant healthcare accessWarningEntitlement and practice

12 HIV medicine records for Uzbekistan are still under review. They have not yet been checked against a national source and must not be read as confirmed access or non-access.

Are HIV medicines reimbursed in Uzbekistan?

Of 26 verified HIV medicine records for Uzbekistan, 5 are available and reimbursed (19%), 0 are available but not reimbursed and 21 are not available. 12 further records are still under review.

Reimbursed 5

Generic TDF/FTC (Emtricitabine/Tenofovir DF), Generic TLD (Tenofovir/Lamivudine/Dolutegravir), Generic TLE (Tenofovir/Lamivudine/Efavirenz), Kaletra, Truvada

Not available 21

Biktarvy, Celsentri, Delstrigo, Descovy, Dovato, Edurant, Genvoya, Intelence, Isentress, Juluca, Odefsey, Pifeltro and 9 more

See every medicine with its source ↓

Is PrEP available and reimbursed in Uzbekistan?

Yes. In SHAPE's review, PrEP is available and reimbursed in Uzbekistan.

PrEP recipients: 883 PrEP recipients (2024; UNAIDS GAM)

UNAIDS GAM 2025 reports 883 people receiving PrEP in 2024. This is a service-use count, not a population coverage percentage, and it does not determine reimbursement. [Source: https://aidsinfo.unaids.org/dataset]

Is DoxyPEP available in Uzbekistan?

SHAPE's review found no national DoxyPEP programme or guideline in Uzbekistan.

No country-specific national DoxyPEP programme was confirmed in this review. WHO's 14 July 2026 guideline conditionally recommends that DoxyPEP may be offered to men who have sex with men and transgender women as part of a comprehensive sexual health package. It prioritizes people with recent or recurrent bacterial STIs and calls for antimicrobial-resistance monitoring; the guideline does not itself establish country-level availability or reimbursement. [Source: https://www.who.int/publications/i/item/9789240124110]

What is the policy on sexuality education in Uzbekistan?

SHAPE classifies the sexuality education framework in Uzbekistan as highly restricted. This describes the national policy framework, not how every school delivers it.

National framework: Health, family and HIV-prevention content is integrated into parts of the curriculum, but no comprehensive rights-based national programme was verified.
Interpretation: The status summarizes the verified policy framework; it does not guarantee uniform classroom delivery.

[Sources: https://www.unesco.org/gem-report/en/peer ; https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexuality-education ; https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFEN_ComprehensiveStudyReport_Online.pdf]

What are the rules on abortion and contraception in Uzbekistan?

SHAPE classifies family planning and abortion rights in Uzbekistan as restricted, combining abortion law and contraception policy.

Abortion: Abortion is available on request through 12 weeks, with later access on specified grounds.
Contraception: The EPF 2026 atlas does not include this country, so a directly comparable contraception-policy score is unavailable.
Interpretation: The status combines legal rules and national policy access; regional availability and individual eligibility may differ.

[Sources: https://abortion-policies.srhr.org/countries/]

Can migrants access healthcare in Uzbekistan?

SHAPE's editorial comparison places migrant healthcare access in Uzbekistan in the middle category (Warning). Entitlement: Status- and payment-based entitlement; emergency-care pathway.

Provider type: Public system / employer or private payment · International migrants (2024): 1,154,963

Access rule: Routine migrant care depends on lawful status, employment arrangements, public-programme eligibility, insurance or direct payment.
Main barriers: Irregular status, costs, documentation and limited continuity restrict access outside emergency or humanitarian pathways.
Migration measure: UN DESA estimates 1,154,963 international migrants at mid-year 2024. This is a point-in-time stock, not the number of people who arrived during 2024. The estimate is based on the foreign-born population. Refugee, asylum-seeker or refugee-like population data are incorporated where indicated by UN DESA.
Origin definition: The origin shares below use country or area of birth for foreign-born estimates and country of citizenship for foreign-citizen estimates. They do not establish a person's nationality, ethnicity, language, reason for migration, legal status, recent-arrival status or undocumented status.
Measurement basis: Foreign-born population + refugee/asylum adjustments (UN DESA code B R)
Evidence note: ECDC indicators use 2024 reports: the foreign-born share is calculated only among diagnoses with known origin; late diagnosis is the country-level share with CD4 <350 cells/µL and is not migrant-specific. Data Unavailable means no sufficiently interpretable value was published; a blank is not zero. The status is an editorial comparison of legal entitlement and practical access and does not apply equally to every migrant group.

Main origins: Russian Federation (75%), Ukraine (10.6%), Belarus (2.3%)

How Uzbekistan compares

Uzbekistan ranks #53 of 53 countries with enough verified HIV medicine records, by share of records that are reimbursed (19%; median 82%).

0%Marker: median of all countries100%

Neighbouring and nearby countries

Turkmenistan19%Tajikistan19%Kyrgyzstan19%Kazakhstan19%

All HIV medicines in Uzbekistan

Medicine	Active ingredient	Class	Status	Evidence and source	Checked
Generic TDF/FTC (Emtricitabine/Tenofovir DF) Multiple (Generics)	Emtricitabine / Tenofovir DF	NRTI	Reimbursed	Provided free of charge under national ARV programs or via international donor support. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Generic TLD (Tenofovir/Lamivudine/Dolutegravir) Multiple (Generics)	Tenofovir DF / Lamivudine / Dolutegravir	INSTI + NRTI/NtRTI	Reimbursed	Procured via Global Fund and state partnerships, distributed free of charge at regional AIDS centers. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Generic TLE (Tenofovir/Lamivudine/Efavirenz) Multiple (Generics)	Tenofovir DF / Lamivudine / Efavirenz	NNRTI + NRTI/NtRTI	Reimbursed	Procured via Global Fund and state partnerships, distributed free of charge at regional AIDS centers. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Kaletra AbbVie	Lopinavir / Ritonavir	PI	Reimbursed	Procured via Global Fund and state partnerships, distributed free of charge at regional AIDS centers. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Truvada Gilead Sciences	Emtricitabine / Tenofovir DF	NRTI	Reimbursed	Procured via Global Fund and state partnerships, distributed free of charge at regional AIDS centers. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Biktarvy Gilead Sciences	Bictegravir / Emtricitabine / TAF	INSTI + NRTI/NtRTI	Not available	High-cost branded regimens are generally not procured as public health systems rely on WHO-prequalified generics. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Celsentri ViiV Healthcare	Maraviroc	Entry Inhibitor	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Delstrigo Merck	Doravirine / Lamivudine / Tenofovir DF	NNRTI + NRTI/NtRTI	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Descovy Gilead Sciences	Emtricitabine / TAF	NRTI	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Dovato ViiV Healthcare	Dolutegravir / Lamivudine	INSTI + NRTI	Not available	High-cost branded regimens are generally not procured as public health systems rely on WHO-prequalified generics. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Edurant Janssen	Rilpivirine	NNRTI	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Genvoya Gilead Sciences	Elvitegravir / Cobicistat / Emtricitabine / TAF	INSTI + NRTI/NtRTI + pharmacokinetic enhancer	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Intelence Janssen	Etravirine	NNRTI	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Isentress Merck	Raltegravir	INSTI	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Juluca ViiV Healthcare	Dolutegravir / Rilpivirine	INSTI + NNRTI	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Odefsey Gilead Sciences	Rilpivirine / Emtricitabine / TAF	NNRTI + NRTI/NtRTI	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Pifeltro Merck	Doravirine	NNRTI	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Prezista Janssen	Darunavir	PI	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Rekambys Janssen	Rilpivirine	Long-Acting NNRTI	Not available	Long-acting injectable rilpivirine used with cabotegravir for maintenance treatment in eligible virologically suppressed patients. The existing Uzbekistan record for the complete Vocabria / Rekambys regimen is classified as 'Not Available', so this required rilpivirine component uses the same access and reimbursement status. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys]	14/09/2026
Rukobia ViiV Healthcare	Fostemsavir	Attachment Inhibitor	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Sunlenca Gilead Sciences	Lenacapavir	Capsid Inhibitor	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Symtuza Janssen	Darunavir / Cobicistat / Emtricitabine / TAF	PI + NRTI/NtRTI + pharmacokinetic enhancer	Not available	High-cost branded regimens are generally not procured as public health systems rely on WHO-prequalified generics. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Tivicay ViiV Healthcare	Dolutegravir	INSTI	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Triumeq ViiV Healthcare	Dolutegravir / Abacavir / Lamivudine	INSTI + NRTI	Not available	High-cost branded regimens are generally not procured as public health systems rely on WHO-prequalified generics. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Vocabria ViiV Healthcare	Cabotegravir	INSTI	Not available	Not registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Vocabria / Rekambys ViiV Healthcare / Janssen	Cabotegravir / Rilpivirine	Long-Acting ART	Not available	Not currently registered or procured in the national health system. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Apretude ViiV Healthcare	Cabotegravir (PrEP)	INSTI (Long-Acting PrEP)	Under review	Long-acting injectable cabotegravir with oral lead-in tablets, for pre-exposure prophylaxis. The EU/EEA-wide marketing authorisation of 19 September 2023 does not extend to this country; national registration, supply and reimbursement were not confirmed during this review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/apretude]	14/09/2026
Emtriva Gilead Sciences	Emtricitabine	NRTI	Under review	Emtricitabine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines for HIV-1 treatment. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Uzbekistan. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva]	14/09/2026
Epivir ViiV Healthcare	Lamivudine	NRTI	Under review	Lamivudine is a nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Uzbekistan. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/epivir]	14/09/2026
Eviplera Gilead Sciences	Rilpivirine / Emtricitabine / Tenofovir DF	NNRTI + NRTI/NtRTI	Under review	A once-daily fixed-dose HIV-1 regimen containing rilpivirine, emtricitabine and tenofovir disoproxil; resistance history and viral-load restrictions apply. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Uzbekistan. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera]	14/09/2026
Kivexa ViiV Healthcare	Abacavir / Lamivudine	NRTI	Under review	A fixed-dose NRTI backbone containing abacavir and lamivudine; HLA-B*5701 screening is required before abacavir treatment. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Uzbekistan. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa]	14/09/2026
Norvir AbbVie	Ritonavir	PI + pharmacokinetic enhancer	Under review	Ritonavir is a protease inhibitor used mainly at low dose as a pharmacokinetic enhancer for other protease inhibitors. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Uzbekistan. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/norvir]	14/09/2026
Retrovir ViiV Healthcare	Zidovudine	NRTI	Under review	Zidovudine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines; it is now generally a specialised or alternative treatment option. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Uzbekistan. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir]	14/09/2026
Rezolsta Janssen	Darunavir / Cobicistat	PI + pharmacokinetic enhancer	Under review	A fixed-dose combination of darunavir and cobicistat used with other antiretrovirals. EMA's CHMP issued a positive opinion on 25 June 2026 for a dispersible formulation and paediatric use from age 3 years and 15 kg. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Uzbekistan. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta]	14/09/2026
Stribild Gilead Sciences	Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DF	INSTI + NRTI/NtRTI + pharmacokinetic enhancer	Under review	A once-daily fixed-dose HIV-1 regimen containing an integrase inhibitor, pharmacokinetic enhancer and two reverse transcriptase inhibitors. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Uzbekistan. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/stribild]	14/09/2026
Viread Gilead Sciences	Tenofovir DF	NtRTI	Under review	Tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor used with other antiretrovirals for HIV-1 treatment; renal and bone monitoring may be relevant. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Uzbekistan. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/viread]	14/09/2026
Yeytuo Gilead Sciences	Lenacapavir (PrEP)	Capsid Inhibitor (Long-Acting PrEP)	Under review	Twice-yearly injectable lenacapavir for pre-exposure prophylaxis; a separate marketing authorisation from Sunlenca, which covers treatment. The EU/EEA-wide marketing authorisation of 26 August 2025 does not extend to this country; national registration, supply and reimbursement were not confirmed during this review. An identical product, Lenacapavir Gilead, received a positive EMA opinion under the EU-M4all procedure for use outside the EU. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo]	14/09/2026
Ziagen ViiV Healthcare	Abacavir	NRTI	Under review	Abacavir is a nucleoside reverse transcriptase inhibitor used in combination therapy; HLA-B*5701 screening is required before treatment. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Uzbekistan. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen]	14/09/2026

Sources

The evidence notes above quote these sources. Each record keeps its own source and last-checked date.

aidsinfo.unaids.org https://aidsinfo.unaids.org/dataset
who.int https://www.who.int/publications/i/item/9789240124110
unesco.org https://www.unesco.org/gem-report/en/peer
who.int https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexua…
bzga-whocc.de https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFE…
abortion-policies.srhr.org https://abortion-policies.srhr.org/countries/
who.int https://www.who.int/europe/health-topics/refugee-and-migrant-health
ecdc.europa.eu https://www.ecdc.europa.eu/en/publications-data/hivaids-surveillance…
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/apretude
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/epivir
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/norvir
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/stribild
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/viread
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen

Explore more

HIV medicine map PrEP and DoxyPEP map Reproductive autonomy map Health equity dashboard All countries

This page is for public information and policy discussion and is not medical or legal advice. Found an outdated record or a newer official source? Tell us.